Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.
Also called NCT01210001
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 499 participants
- Registry
-
NCT01210001 -
2009-016154-40
-
- Other papers using this trial's data
- Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- United States, Canada, Greece, India, Philippines, Thailand, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01210001. Randomized; double masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2014-06-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01210001- Content hash
68b3f0fbd50f867742995720de83996966cdfe1da0480c3912d3b31b8f428668